DeDora Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

DeDora Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-21	Closed	-$3K	–	254
2022 Q1	$3K	Buy	+21	New	+$3.05K	﹤0.01%	362

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

DeDora Capital's JAZZ Position: Q2 2022 in Review

DeDora Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2022, closing a stake of 21 shares — an estimated $3K sold.

DeDora Capital first reported a position in JAZZ in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q2 2022.

DeDora Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
DeDora Capital sold 21 Jazz Pharmaceuticals shares in Q2 2022, an estimated $3K.
DeDora Capital first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 1 quarter.
DeDora Capital's Jazz Pharmaceuticals position peaked at $3K in Q1 2022.
468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2022.

Based on DeDora Capital's 13F filing for Q2 2022, filed 27 Jul 2022.